Japanese Biotechs Develop Quicker Diagnostic For Cancer Metastases
This article was originally published in PharmAsia News
Executive Summary
Japan's Sysmex and Oncolys BioPharma say they have developed technology to use certain viruses in detecting living tumor cells as they are suspended in blood. Circulating tumor cells are blamed for cancer metastasis, but conventional diagnostics are able to detect their presence only through the proteins they secrete, and that in turns helps in identifying the size of the metastatis. Sysmex says the method it and Oncolys developed jointly allows for early detection of a possible metastasis by using a virus that replicates and emits fluorescence. (Click here for more
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.